

**Biomarkers for the Prediction and Early Diagnosis of Diabetes and Diabetes-related Cardiovascular Complications (PREDICt)**  
– University Medical Center Groningen (UMCG), Groningen



Principal Investigator: Prof. Dr. M. H. Hofker  
CTMM Program manager: Erna Erdtsieck-Ernste

Type 2 Diabetes Mellitus (DM2) affects more than 500,000 people in the Netherlands alone, and by the time it is diagnosed, life-threatening complications such as myocardial infarction, cerebro-vascular incidents and kidney failure have often occurred. Early diagnosis and treatment of DM2 is therefore essential to reduce the burden of this disease and its complications on individuals and the healthcare system.

The PREDICt (Prevention and Early Detection of Cardiovascular Complications in DM2) consortium will combine the latest insights into the causes of DM2 with innovative technologies to identify risk-indicators (biomarkers) for DM2 and DM2-related complications with the objective of:

1. identifying people at risk of obesity and DM2
2. identifying DM2 patients with an increased risk of cardiovascular complications
3. gaining insight into strategies to diagnose diabetic vascular disease at an early stage

In the search for these biomarkers, the PREDICt project will adopt two complementary strategies. Firstly, by leveraging important new insights into the phenomena leading to DM2 and its complications in order to develop novel technologies for visualizing the associated processes, and identifying biomarkers that represent a relation between these phenomena and DM2. Secondly by identifying biomarkers in DM2 patients in whom the presence or absence of complications has been established, it will provide accurate information on their disease phase.

For more information, visit the website of CTMM:

<http://www.ctmm.nl/pro1/general/start.asp?i=3&j=6&k=0&p=0&itemid=121>